Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381

1.1 Olaparib is recommended within its marketing authorisation as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum based chemotherapy only if:

• they have had 3 or more courses of platinum based chemotherapy and

• the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company.

1.2 People whose treatment with olaparib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta381